US. FDA issues Form 483 with four observations to Aurobindo Pharma

May 19, 2023 09:48 pm | Updated 09:48 pm IST - HYDERABAD

The U.S. Food and Drug Administration has issued a Form 483 with four observations to Aurobindo Pharma after inspecting the company’s (Unit XIV) active pharmaceutical ingredient manufacturing facility in Andhra Pradesh.

The API non-antibiotic manufacturing facility in Paravada Industrial Area, Anakapalli district, was inspected from May 15-19. “We have been issued a Form 483 with four observations [which] are procedural in nature,” Aurobindo said. The company said it will respond within the stipulated timelines and work closely with regulator to close the observations at the earliest.

On Friday, Aurobindo shares closed 1.64% lower at ₹589.45 each on the BSE.

Top News Today

Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in


Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.